WASHINGTON, D.C. (LifeSiteNews) — The U.S. Food and Drug Administration (FDA) has approved a new version of the abortion pill, in a stark contradiction to the Trump administration’s promises of a more critical approach to abortion drugs.
Reuters reports that the FDA approved generic mifepristone tablets, manufactured by Evita Solution and sold with the help of GenBioPro. Evita’s stated mission is to “normalize abortion” and make it “accessible to all.”
“We have determined your Mifepristone Tablets, 200 mg to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Mifeprex (mifepristone) tablets, 200 mg, of Danco Laboratories,” the September 30 letter reads.
READ: Abortion pill injuries are massively underreported due to activists, complicit media: new report
Many conservative and pro-life voices responded with shock and outrage to the news. “FDA had promised to do a top-to-bottom safety review of the chemical abortion drug, but instead they’ve just greenlighted new versions of it for distribution,” said U.S. Sen. Josh Hawley (R-MO). “I have lost confidence in the leadership at FDA.”
“This drug starves babies and harms mothers! The FDA just said it would do a new serious safety study – so why approve a another generic now?” asked Live Action founder Lila Rose. “This reckless move doesn’t protect women – it empowers abusers and tramples pro-life laws across the country,” SBA Pro-Life America said.
“The Pro-Life Generation asked during the campaign and from day one in this new administration for one Republican President to undo the political manipulations of three Democratic Party Presidents who prioritized the business model of Chemical Abortion Pill pushers,” Students for Life president Kristan Hawkins said. “More babies will die; More women will be harmed; and More Americans exposed to Abortion Water Pollution as a direct result of this unfathomable decision. This is a stain on the Trump Presidency and another sign that the deep state at the FDA must go.”
Many pro-lifers expressed fear during the 2024 Republican primaries about how pro-life a second Trump administration would really be, because despite the generally pro-life record of his first term, President Donald Trump made clear since 2022 he wanted the Republican Party to chart a more “moderate” position on abortion, including removing a support for a federal ban from the party platform and declaring he would not enforce a federal law prohibiting abortion pills from being dispensed by mail.
After returning to office, Trump took a number of pro-life actions that caused pro-lifers to relax, primarily in the area of taxpayer funding. Pro-lifers further hoped that a strengthening of his abortion pill position would eventually follow, bolstered by promises from U.S. Health & Human Services Secretary Robert F. Kennedy Jr. (another formerly pro-abortion figure who “moderated” during his own presidential bid) has promised a “complete review” of the risks of abortion pills.
Approving a generic as “bioequivalent and therapeutically equivalent to” Mifeprex does not technically preclude such a review from eventually pulling both from the market in the future but makes abortion pills more available and affordable in the interim, rather than the bare minimum pro-lifers would have expected of suspending all such approvals until a conclusion was reached about the original.
The matter is particularly urgent in light of the fact that unregulated, no-oversight distribution of abortion pills across state lines has become arguably the abortion lobby’s most effective tactic for circumventing state pro-life laws, as pills can be mailed, received, and taken in complete privacy, without any sign law enforcement can act on.